article · Cancer Control
Detection of <i>KRAS</i> mutations, particularly the G12 C subtype, may be significant for patients with CRC and has possible therapeutic implications. However, rare <i>KRAS</i> concomitant mutations in CRC patients suggest that each individual may present distinct therapeutic responses. <i>KRAS</i> testing alongside the identification of other affected genes in the same patient will make the treatments even more personalized by contributing more accurately to the clinical decision process. Overall, early diagnosis using novel molecular techniques may improve the management of CRC by providing the most efficient therapies for Moroccan patients.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1177/10732748241262179
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
